24 results
6-K
EX-99.3
ACIU
AC Immune SA
4 Aug 23
Current report (foreign)
7:30am
2024
ACI-7104.056
anti-a-syn active immunotherapy
Completion of recruitment of first cohort in the Phase 2 VacSYn study in Parkinson’s disease expected
6-K
EX-99.1
ACIU
AC Immune SA
2 Aug 22
Detailed data from the phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented at AAIC
11:12am
endpoints needed to rapidly test promising prevention therapies. It also leads participant recruitment registries to accelerate enrolment into Alzheimer’s
6-K
EX-99.1
ACIU
AC Immune SA
16 Jun 22
AC Immune provides update on Alzheimer’s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer’s disease
7:38am
promising prevention therapies. It also leads participant recruitment registries to accelerate enrollment into Alzheimer’s-focused studies. API
6-K
EX-99.2
75wakth
23 Mar 21
AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook
9:06am
6-K
EX-99.2
k04q0g8
13 Nov 20
Current report (foreign)
8:03am
6-K
EX-99.2
r3fkn5s9eyayzgjnc
5 Aug 20
Current report (foreign)
7:29am
6-K
EX-99.2
9qy2yt1f
4 May 20
Current report (foreign)
8:32am
6-K
EX-99.1
h1b82yld
28 Jun 19
Current report (foreign)
4:45pm
6-K
EX-99.1
eor e9qm7
4 Jun 19
Invitation to the Ordinary Shareholders' Meeting
7:22am
6-K
EX-99.3
hmvf711vnhcex04bip8v
15 May 19
Current report (foreign)
7:43am
6-K
EX-99.1
mzalw24 us99azoe
21 Mar 19
Current report (foreign)
7:44am
6-K
EX-99.3
ktp 5hkvbl6p5noa
13 Nov 18
Current report (foreign)
6:05am
6-K
EX-99.3
d9pbka
8 Aug 18
Current report (foreign)
6:01am
6-K
EX-99.1
v9gqkv3nnv60b
17 Jul 18
Updates on AC Immune’s Pipeline and Technology Platforms to be presented at the Alzheimer’s Association International Conference in Chicago
6:00am
6-K
EX-99.1
ei462y7ht7wb8zdc2k
6 Jul 18
Current report (foreign)
4:37pm